"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A trial of custirsen with docetaxel for prostate cancer that has spread (SYNERGY)
- cancer had spread to other parts of the body (advanced cancer)
- hormone therapy had stopped working
More about this trial
Cancer that has spread elsewhere in the body is called advanced cancer. Docetaxel chemotherapy is a usual treatment for advanced prostate cancer if hormone therapy has stopped working. Treatment might also include a
In this trial, doctors looked at adding a type of targeted drug called custirsen (OGX-011) to improve treatment.
Some cancer cells produce a lot of a protein called clusterin. This may help them to protect themselves from cancer drugs and stop the drugs working as well as they could. Custerin reduces the level of clusterin. Researchers hoped that by lowering the levels of clustirsen, the cancer drugs would work better.
In this trial, some men had docetaxel, prednisolone and custirsen. And some had docetaxel and prednisolone.
The aim of the trial was to see if adding custirsen to docetaxel and prednisolone improved treatment for advanced prostate cancer.
Summary of results
- 512 had docetaxel and prednisolone
- 510 had docetaxel, prednisolone and custirsen
- 22 months in men who had docetaxel, prednisolone and custirsen
- just over 23 months (23.4) in men who had docetaxel and prednisolone
- an increased risk of infection
- low levels of
white blood cellswith a fever
- a drop in the number of red blood cells (
- liver changes
- weakness or lack of energy
How to join a clinical trial
Professor Johann de Bono
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Teva Pharmaceutical Industries Ltd